Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06357533
Title Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC >/= 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)
Acronym TROPION-Lung10
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca
Age Groups: adult | senior
Covered Countries USA | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS

Additional content available in CKB BOOST